Request Demo
Xenetic to advance DNase programme with UVA partnership
18 Jan 2024
License out/inImmunotherapyClinical Study
Under the agreement, the parties will develop Xenetic’s DNase-based platform. Credit: Maksim Shmeljov/Shutterstock.com.
Xenetic Biosciences has entered into research Xenetic and material transfer agreements with the University of Virginia (UVA) in the US to advance its systemic deoxyribonuclease (DNase) programme.
Xenetic Biosciencesvelop Xenetic’s DNase-based oncology platform.University of Virginia (UVA)
The platform acts on neutXeneticextracellular traps (NETs), weblike structures that comprise extracellular chromatin covered with histones and other proteins.
The new initiative addresses NETs associated with inflammatory and autoimmune diseases, as well as cancer progression.
Excessive levels of NETs can create pro-tumorigeniinflammatory and autoimmune diseaseseness of canccancerrapies.
The platform is designed to complement existing cancer treatments including immunotherapies.cancer
The agreements grant Xenetic an option to solelycancerse any new intellectual property resulting from the DNase research programme. This is in addition to advancing the existing intellectual property of Xenetic.
The company is preparing for a first-in-human clinical trial to assess DNase plus immune checkpoint inhibitors or chemotherapy.
Xenetic CEO Jeffrey Eisenberg stated: “We believe the data generated by our researimmune checkpoint inhibitorsimmune checkpoint inhibitorsimmune checkpoint inhibitorstions are key to fully unlocking the potential of our DNase technology and importantly, providing translational insights as we drive a clinical path for our lead solid tumour indications.
Xeneticagreements provide a significant addition to our development capabilities and resources, and we believe it bolsters our opportunity to accelerate development timelines.solid tumour
“Additionally, we are pleased to deepen our work with Dr Tsung, who has provided a valuable perspective to our team and significant insight for our DNase platform.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.